Drugs in the Pipeline, News
Rilzabrutinib Fails in Phase 3 Pemphigus Trial
Rilzabrutinib is an oral Bruton tyrosine kinase inhibitor currently in development for a number of immune-mediated diseases.
Your search for oral corticosteroids returned 4 results
Drugs in the Pipeline
Phase 3 Study of ACZ885 for Children with Systemic Juvenile Idiopathic Arthritis
Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).
Drugs in the Pipeline
Phase 3 Study of Masitinib for the Treatment of Asthma
AB Science announced the recruitment of the first patient in its Phase 3 study evaluating masitinib for severe persistent asthma.
Drugs in the Pipeline
Phase 3 study of LX211 (Luveniq) for uveitis
Lux Biosciences reported the results from three Phase 3 LUMINATE trials of the company's LX211 (Luveniq, voclosporin capsules) drug candidate for the treatment of uveitis.
